Neurocrine Biosciences, Inc. (LON:0K6R)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 11.60B +47.4% |
| Revenue (ttm) | 2.35B +28.6% |
| Net Income | 506.33M +118.6% |
| EPS | 4.92 +119.9% |
| Shares Out | n/a |
| PE Ratio | 22.91 |
| Forward PE | 13.21 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 487 |
| Average Volume | 284 |
| Open | 157.98 |
| Previous Close | 155.41 |
| Day's Range | 153.02 - 159.55 |
| 52-Week Range | 116.21 - 161.05 |
| Beta | 0.34 |
| RSI | 78.40 |
| Earnings Date | May 5, 2026 |
About Neurocrine Biosciences
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical develo... [Read more]
Financial Performance
In 2025, Neurocrine Biosciences's revenue was $2.86 billion, an increase of 21.45% compared to the previous year's $2.36 billion. Earnings were $478.60 million, an increase of 40.23%.
Financial numbers in USD Financial StatementsNews
Neurocrine Biosciences Transcript: Bank of America Global Healthcare Conference 2026
Strong Q1 performance was driven by INGREZZA, CRENESSITY, and the addition of VYKAT XR, with all products showing durable growth and long patent protection. The pipeline is robust, with key phase III readouts expected in 2027–2028, and the Soleno acquisition is immediately accretive.
Neurocrine price target raised to $185 from $177 at JPMorgan
JPMorgan analyst Anupam Rama raised the firm’s price target on Neurocrine (NBIX) to $185 from $177 and keeps an Overweight rating on the shares.
Neurocrine price target raised to $155 from $140 at Truist
Truist analyst Danielle Brill raised the firm’s price target on Neurocrine (NBIX) to $155 from $140 and keeps a Buy rating on the shares. Both Ingrezza and Crenessity sales exceeded…
Neurocrine price target raised to $155 from $150 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Neurocrine (NBIX) to $155 from $150 and keeps a Hold rating on the shares.
Neurocrine treatment of Friedreich ataxia granted orphan designation
Neurocrine (NBIX) Biosciences was granted FDA orphan designation for a treatment of Friedreich ataxia, according to a post to the agency’s website.
Neurocrine price target raised to $246 from $242 at Citi
Citi analyst Yigal Nochomovitz raised the firm’s price target on Neurocrine (NBIX) to $246 from $242 and keeps a Buy rating on the shares. The company reported a Q1 beat…
Neurocrine price target raised to $207 from $190 at Piper Sandler
Piper Sandler raised the firm’s price target on Neurocrine (NBIX) to $207 from $190 and keeps an Overweight rating on the shares following quarterly results. Taking a step back, the…
Neurocrine price target raised to $191 from $185 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Neurocrine (NBIX) to $191 from $185 and keeps an Equal Weight rating on the shares. Neurocrine delivered a “strong” Q1 and Ingrezza…
Neurocrine price target raised to $230 from $220 at Oppenheimer
Oppenheimer raised the firm’s price target on Neurocrine (NBIX) to $230 from $220 and keeps an Outperform rating on the shares. The firm’s conviction in Neurocrine strengthened following impressive Q1...
Neurocrine price target raised to $155 from $140 at Truist
Truist analyst Danielle Brill raised the firm’s price target on Neurocrine (NBIX) to $155 from $140 and keeps a Buy rating on the shares. The firm updated its Neurocrine model…
Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia
New algorithms developed by expert clinical endocrinologists provide clear, practical recommendations for healthcare providers to reduce supraphysiologic glucocorticoid (GC) doses in patients with cla...
Neurocrine Biosciences Earnings Call Transcript: Q1 2026
Q1 2026 saw record net product sales over $800M, up 44% year-over-year, led by INGREZZA and CRENESSITY. Strong commercial execution, robust pipeline progress, and the pending Soleno acquisition position the company for continued growth in 2026.
Neurocrine reports Q1 adjusted EPS $1.94, consensus $1.70
Reports Q1 revenue $811M, consensus $767.88M. “Neurocrine’s (NBIX) strong first-quarter performance reflects continued momentum across our commercial portfolio, as we advance our growth strategy and d...
Neurocrine backs FY26 Ingrezza net product sales $2.7B-$2.8B
16:02 EDT Neurocrine (NBIX) backs FY26 Ingrezza net product sales $2.7B-$2.8B
Neurocrine Biosciences Reports First-Quarter 2026 Financial Results
Total First-Quarter 2026 Net Product Sales of $811.0 Million, An Increase of 44% Year-Over-Year Announced Definitive Agreement to Acquire Soleno Therapeutics, Including VYKAT TM XR (diazoxide choline)...
Neurocrine Biosciences to Present at the Bank of America Health Care Conference 2026
SAN DIEGO, May 5, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that its executives will participate at the Bank of America Health Care Conference 2026 at 11:20 a.m....
Neurocrine Biosciences Announces New Survey Results Showing Significant Burden of Tardive Dyskinesia on Employment
Approximately 1 in 5 surveyed working adults with tardive dyskinesia reported quitting their job due to untreated involuntary movements1 Respondents also reported missing an average of 8 hours of work...
Neurocrine initiates Phase 1 study of NBIP-‘2118
Neurocrine (NBIX) Biosciences announced the initiation of a Phase 1 first-in-human clinical study evaluating the safety and tolerability of NBIP-‘2118 in adult participants. NBIP-‘2118 is an investiga...
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'2118, a Corticotropin-Releasing Factor Type 2 Receptor Agonist
NBIP-'2118 targets a new, non-incretin mechanism for weight loss with lean mass preservation SAN DIEGO, May 4, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the init...
Neurocrine presents two-year Crenessity data
Neurocrine (NBIX) Biosciences announced the presentation of new two-year data from the Phase 3 CAHtalyst Pediatric study demonstrating durable androgen control, sustained decreases in glucocorticoid d...
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Durable Hormone Control, Reduced Glucocorticoid Exposure and Meaningful Clinical Improvements in Pediatric Patients with Classic Congenital Adrenal Hyperplasia
At two years, 60% of patients who were overweight or obese at baseline experienced clinically meaningful improvements in body mass index, and 61% of those with insulin resistance at baseline were no l...
Neurocrine Biosciences Announces Publication Establishing Clinically Meaningful Improvement Threshold for the Tardive Dyskinesia Impact Scale
Research published in The Journal of Clinical Psychiatry characterizes patient-reported improvement with INGREZZA® (valbenazine) capsules across the KINECT® clinical program Publication establishes a ...
Neurocrine’s Crenessity enables glucocorticoid dose reduction in CAH study
Neurocrine (NBIX) announced the first presentation of new two-year data from the Phase 3 CAHtalyst Adult study demonstrating sustained, substantial reductions in glucocorticoid, or GC, doses in adults...
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital Adrenal Hyperplasia
Approximately 70% of adult patients treated with CRENESSITY achieved and sustained physiologic‑range glucocorticoid dosing at two years 75% of patients originally taking dexamethasone transitioned off...
Wells Fargo downgrades Soleno on pending acquisition
Wells Fargo downgraded Soleno Therapeutics (SLNO) to Equal Weight from Overweight with a price target of $53, down from $110. The firm cites Neurocrine’s (NBIX) pending acquisition of the company…